Meeting Banner
Abstract #2919

In vivo OE-MRI quantification and mapping of response to hypoxia modifying drugs Banoxantrone and Atovaquone in Calu6 xenografts

Ross A Little1, Victoria Tessyman2, Muhammad Babur2, Susan Cheung1, Yvonne Watson1, Roben Gieling2, Katherine G Finegan2, Thomas M Ashton3, Geoff JM Parker1,4, W Gillies Mckenna3, Geoffrey Higgins3, Kaye J Williams2,5, and James PB O'Connor5,6

1Centre for Imaging Sciences, University of Manchester, Manchester, United Kingdom, 2Manchester Pharmacy School, University of Manchester, Manchester, United Kingdom, 3CRUK/MRC Oxford Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom, 4Bioxydyn Ltd, Manchester, United Kingdom, 5Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom, 6Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom

Oxygen-enhanced MRI (OE-MRI) has shown promise as a technique for quantifying and spatially mapping tumour hypoxia. Here we report the first evidence that OE-MRI signals in perfused tumour can non-invasively track therapy-induced changes in hypoxia in vivo in a tumour model. We show that OE-MRI detects (1) reduction in hypoxia and increase in necrosis induced by the hypoxia-activated cytotoxic prodrug Banoxantrone; and (2) reduction in hypoxia and increase in well oxygenated tumour induced by Atovaquone due to increased oxygen availability. These data support first-in-man use of OE-MRI biomarkers in clinical trials of hypoxia-modifying agents.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract